ABSTRACT Background: The role of sugar-sweetened beverages (SSBs) that contain free or bound fructose in the pathogenesis of hypertension remains unclear. Objective: We conducted a systematic review and meta-analysis of prospective cohort studies to quantify the association between fructose-containing SSBs and risk of hypertension. Design: MEDLINE, Embase, Cumulative Index to Nursing and Allied Health Literature, and the Cochrane registry were searched from conception through 11 November 2014. Two independent reviewers extracted data and assessed the quality of studies (with the use of the Newcastle-Ottawa Scale). Risk estimates of extreme quantiles of SSB intake (lowest vs. highest) for hypertension incidence were generated with the use of generic inverse-variance methods with random-effects models and expressed as risk ratios with 95% CIs. Heterogeneity was assessed with the Cochran Q statistic and quantified with the I 2 statistic. Results: Six prospective cohort studies (n = 240,508) with 79,251 cases of hypertension observed over $3,197,528 person-years of follow-up were included. SSB consumption significantly increased the risk of developing hypertension by 12% (risk ratio: 1.12; 95% CI: 1.06, 1.17) with evidence of significant heterogeneity (I 2 = 62%, P = 0.02) when highest ($1-serving [6.7, 8 or 12 oz]/d) and lowest (none) quantiles of intake were compared. With the use of a dose-response analysis, a significant 8.2% increase in risk of every additional SSB per day from none to $1 SSB/d (b = 0.0027, P , 0.001) was identified. Limitations include unexplained heterogeneity and residual confounding. The results may also have been subject to collinearity effects from aspects of a Western dietary pattern. Conclusions: SSBs were associated with a modest risk of developing hypertension in 6 cohorts. There is a need for high-quality randomized trials to assess the role of SSBs in the development of hypertension and its complications. This study was registered at clinicaltrials.gov as NCT01608620. Am J Clin Nutr
INTRODUCTION
Hypertension is a major risk factor for cardiovascular disease and accounts for 9.4-million deaths annually, worldwide (1) . Nevertheless, hypertension risk remains highly modifiable through dietary and lifestyle interventions (2) . Recent attention has implicated sugar-sweetened beverage (SSB) 12 intake in the pathogenesis of hypertension, as well as other chronic diseases including obesity and diabetes (3) . Public health initiatives that aimed to reduce SSB intakes have included recommendations for front-of-package warning labels in Canada (4), SSB portion-size restrictions in New York City (5) , and the introduction of a SSB tax in the United Kingdom (6) .
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*To whom correspondence should be addressed. E-mail: john.sievenpiper@ utoronto.ca. (7) (8) (9) . It has been suggested that fructose, through the depletion of ATP that leads to an elevation of uric acid, induces vascular oxidative stress, endothelial dysfunction, and aggravates the reninangiotensin axis, consequently elevating blood pressure (8) . Animal studies and select human trials of overfeeding offructose-containing sugars as well as low-quality observational studies have been used to buttress this relation (10) . However, higher-quality evidence from systematic reviews and meta-analyses of controlled feeding trials on the effects of monosaccharide fructose on blood pressure (11) and uric acid (12) compared with other calorically matched carbohydrates and prospective cohorts of the relation between fructose intake and hypertension risk (13) have not supported this association.
Despitetheuncertainties,thereismountingpressureonguideline committees to implicate fructose-containing SSBs in the development of hypertension (7, 14) . To synthesize the evidence from prospective cohort studies, we conducted a systematic review and meta-analysis of prospective cohorts to assess the relation between SSB intake and risk of developing hypertension.
METHODS

Design
TheCochraneHandbookforSystematicReviewsofInterventions (15) and the Meta-analysis of Observational Studies in Epidemiology guidelines (16) were followed in conducting and reporting this meta-analysis. The protocol was registered (clinicaltrials.gov; NCT01608620).
Study selection
WesearchedMEDLINE(http://www.ncbi.nlm.nih.gov/pubmed/), Embase (http://www.elsevier.com/solutions/embase), Cumulative Index to Nursing and Allied Health Literature (https://www. ebscohost.com/nursing/products/cinahl-databases/cinahl-complete), and the Cochrane Registry (http://www.cochranelibrary.com/about/ central-landing-page.html) through to 11 November 2014 with the use of the following inclusive search term: (fructose*.mp OR sucrose*.mp OR HFCS*.mp OR honey*.mp OR sugar*.mp) AND (hypertensive.mp OR hypertension.mp OR HTN.mp) (Supplemental Table 1 ). Manual searches of reference lists supplemented database searches. Only prospective cohorts that reported data on the association of SSBs and incident hypertension were included in our analysis.
Data extraction
Studies wereinitially excludedonthe basisoftitlesandabstracts. Next, 2 independent reviewers (VHJ and VH) fully reviewed the remaining articles, producing a final list of prospective cohorts to meta-analyze. A kappa statistic (ĸ) was calculated to quantify between-reviewer agreement (0 = completely disagree, 1 = completely agree). To quantify between-reviewer agreement, a kappa (ĸ) statistic was calculated (0 = completely disagree, 1 = completely agree). A standardized pro forma was used in extracting all cohort characteristics. The RR of developing hypertension at each quantile of SSB intake was extracted alongside: authorship, background dietary pattern, cohort name, covariates included in the most-adjusted models, duration, person-years of follow-up, participant characteristics (age, sex, health status), publication year, sample size, and SSB exposure level (as percentage of energy). Sex-specific data were used wherever provided.
Study quality
The Newcastle-Ottawa Scale for Cohort Studies was used to assess cohort quality. A maximum of 9 points were awarded on the basis of the cohort selection (#4 points), the comparability of the cohort design and analysis (#2 points), and the adequacy of outcome measures (#3 points) (17); $6 points was considered high quality. Disagreements in score allocations were resolved by consensus.
Statistical analyses
We pooled ln-transformed RRs for incident hypertension to compare the highest quantile of SSB exposure with the lowest quantile of SSB exposure (reference group) with the use of the generic inverse-variance method with random-effects modeling. Results were reported as risk ratios with 95% CIs. Between-cohort heterogeneity was tested with the use of Cochran's Q (chi-square) statistic at a , 0.10 and quantified with the use of the I 2 statistic; an I 2 $ 50% indicated evidence of considerable heterogeneity. A priori subgroups, which were used to investigate the interstudy heterogeneity, included disease status, sex (men vs. women), follow-up (,10 vs. $10 y), adjustments for critical covariates [age, race, family history, physical activity, smoking status, body weight and BMI (in kg/m 2 ), and total caloric intake], and study quality (Newcastle-Ottawa scale: 6, vs. $6). Meta-regressions with dummy variables that represented subgroup levels were used when testing for between-subgroup differences. Sensitivity analyses of systematically removing individual cohorts from the primary analysis and recalculating the pooled risk ratios were performed to clarify the contribution of individual cohorts to the overall association. The possibility of a dose-response relation was explored with the use of random-effects generalized least-squares trend estimation (GLST) models. We evaluated the possibility of a nonlinear relation with the use of a Wald test for the goodness-offit of the regression whereby a significant result indicated evidence of heterogeneity or unaccounted-for bias in the fitted linear GLST model, and a nonsignificant result indicated no departure from linearity (18) . Five of 6 cohorts provided data for dose-response analyses; because most data were reported as servings of SSBs per month, all levels of exposure were converted to this common unit to mitigate errors resulting from unnecessary imputations. Publication bias was assessed by visually inspecting funnel plots and formally tested with Egger's and Begg's tests, where P , 0.10 was considered evidence of bias. Primary pooled analyses were conducted with the use of Review Manager software (RevMan, version 5.1.7; The Nordic Cochrane Centre, The Cochrane Collaboration). Assessments of publication bias, dose responses, and subgroup differences were performed with the use of STATA SE version 12.1 software (StataCorp LP). Table 1 summarizes individual cohort characteristics. Together, the 6 cohorts included 240,508 participants and 79,251 cases of hypertension with .3,197,528 person-years of follow-up. Personyear data were not presented for CARDIA. The CARDIA and SUN cohorts followed young (n = 2774; age: 18-30 y) and middle-aged (n = 13,843; age: 20-91 y) men and women, respectively, whereas the other cohorts followed older men (HPFS: n = 37,360; age: 42-63 y) or older (NHS-I: n = 88,540; age: 38-53 y) and middle-aged (NHS-II: n = 97,991; age: 31-40 y) women. Four cohorts were of US origin, and 2 cohorts were of Spanish origin, with a median follow-up of 18 y (range: 2-28 y). The incidence of hypertension (systolic blood pressure $130 mm Hg or diastolic blood pressure $85 mm Hg in CARDIA; systolic blood pressure $140 mm Hg or diastolic blood pressure$90 mm Hg in HPFS, NHS-I, NHS-II, and SUN) was ascertained from self-reported physician diagnoses. SSB intake, in 8-oz servings (236-mL; CARDIA), 7-oz servings (200-mL; SUN), or 12-oz servings (355-mL; HPFS, NHS-I, and NHS-II) was assessed with the use of validated diet-history food-frequency questionnaires. Data were collected quadrennially in HPFS, NHS-I, and NHS-II; biennially in SUN; and at years 0, 7, and 20 in CARDIA. HFPS, NHS-I, and NHS-II reported HRs in quarts ranging from ,1 SSB/mo to $1 SSB/d; CARDIA reported RRs in dichots whereby years 0 and 7 were averaged for the baseline and compared with year 20 at extreme intakes (none vs. frequent); and SUN reported RRs in tertiles ranging from nondrinkers to $1-serving/d. All cohorts adjusted for major risk factors of hypertension (age, race, family history, physical activity, smoking status, and body weight and BMI) and total caloric intake. In addition, CARDIA adjusted for milk intake, fruit juice intake, and CARDIA exam center; HPFS, NHS-I, and NHS-II adjusted for artificially sweetened beverages, the Dietary Approaches to Stop Hypertension-style diet, and total fructose intake; and SUN adjusted for self-reported hypercholesterolemia, years of university education, energy-adjusted sodium, potassium, low-fat dairy, olive oil, fruit, vegetables, cereals, legumes, meat, whole-fat dairy, fish, and alcohol consumption (Supplemental Table 2 ). The study quality was high for all cohorts.
RESULTS
Search results
Trial characteristics
Total SSB intake on incident hypertension Figure 2 presents the meta-analyzed association between SSB intake and incident hypertension. The risk of developing hypertension was 12% greater (risk ratio: 1.12; 95% CI: 1.06, 1.17; P , 0.001) Dietary information was collected with the use of validated semiquantitative food-frequency questionnaires. 3 Quintiles were calculated as the number of beverages consumed. 4 Calculated by adding the number of cases through all quintiles. 5 Calculated by adding the number of person-years through all quintiles. 6 Quality score was assessed with the use of the NewCastle-Ottawa Assessment Scale for Cohort Studies whereby a maximum of 10 points could be awarded. 7 From a government, university, or not-for-profit health agency.
in individuals in the highest compared with the lowest quantiles of SSB intake. We observed significant between-cohort heterogeneity (I 2 = 62%, P = 0.02).
A priori subgroup and sensitivity analyses
Only 2 (duration and sex) of 5 a priori analyses were performed because the cohorts did not vary according to the remaining 3 analyses (disease status, study quality, and adjustments for critical covariates). Subgroup meta-regressions for neither sex (men, women, and both) nor duration (as a continuous variable: 2-28 y) explained the heterogeneity in our results (men vs. women: P = 0.37; women vs. both: P = 0.27; men vs. both: P = 0.88; duration: P = 0.25). The systematic removal of individual cohorts did not modify the overall significance nor the direction of the overall association although the heterogeneity in our results was reduced (I 2 , 50%) with the removal of the NHS-II.
Dose-response relations
HPFS, NHS-I, NHS-II, SUN-Male, and SUN-Female were analyzed for a dose-response; CARDIA was excluded because information regarding person-years or quantitative intakes were unavailable. We observed a significant positive random-effects GLSTdoseresponsebetweenSSBintakeandincidenthypertension [b = 0.0027 (95% CI: 0.0021, 0.0033); P , 0.001]; the risk of hypertension increased 0.27% for every additional SSB per month or 8.2% for every additional SSB per day across exposures ranging from none to $1 SSB/d (Supplemental Figure 1) . The Wald test for a nonlinear regression indicated no departure from linearity (P = 0.17).
Publication bias
Visual inspection of funnel plots and formal testing with Egger's and Begg's tests did not reveal significant evidence of publication bias (Egger's P = 0.75, Begg's P = 0.57) (Supplemental Figure 2) .
DISCUSSION
This systematic review and meta-analysis of 6 prospective cohorts of 240,508 individuals, with .3,197,528 person-years of follow-up and 79,251 hypertension cases showed a modest 12% greater risk of developing hypertension when comparing the highest intake ($1 SSB/d) with the lowest intake (none). There was significant heterogeneity observed between cohorts, which was not explained by differences in sex or the duration of followup. We observed a significant positive linear dose response (b = 0.0027) per additional serving of SSB per month in pooling of 5 of 6 cohorts.
Findings in the context of the literature
Our results are consistent with evidence from prospective cohorts linking SSB intake with the possible downstream effects of hypertension, namely coronary heart disease and stroke (22, 23) , although the evidence remains less robust for these relations. SSB intake has been positively associated with coronary heart disease riskinwomenonly (24) andstrokeincidenceinwomen,butnotmen, in the NHS, HPFS (25) , and Japan Public Health Centre-based Study Cohort I (26) .
Several mechanisms may explain the current results. One proposed mechanism is that liquid calories from SSBs elicit a weaker satiety response than do solid calories, potentially leading to decreases in the compensation for liquid calories and increases in subsequent energy intake, weight gain, and cardiometabolic morbidity (23) . Although a systematic review of 121 liquid preload interventions showed this relation existed acutely (27) , longer-term trials that compared liquid with solid calories on food intake have not shown a significant increase in long-term caloric overconsumption or weight gain (28, 29) . More long-term trials are needed to confirm these findings.
Another potential mechanism is that SSBs may represent a marker of an unhealthy lifestyle that predisposes individuals to hypertension (30, 31) . People who consume more SSBs tend to consume more calories, exercise less, smoke more, and drink more alcohol (20) .TheyarealsomorelikelytoconsumeaWesterndietary pattern, which includes higher intakes of refined grains, French fries, processed meat, red meat, sweets, and desserts (30, 32, 33) , which are high in sodium, glycemic index, and also independently associated with obesity.
A final mechanism implicates the fructose moiety within SSBs as the culprit (7) (8) (9) . This link between fructose and hypertension is not well supported. High-level evidence from systematic reviews and meta-analyses of controlled feeding trials have shown no FIGURE 2 Forest plot of prospective cohorts that investigated the association between sugar-sweetened beverage intake and incident hypertension. The pooled-effect estimate is represented as a diamond. P values are for generic inverse variance random-effects models. Interstudy heterogeneity was assessed via Cochran's Q (chi-square) statistics at a significance of P , 0.10 and quantified with the use of the I 2 statistic where I 2 . 50% was considered to be evidence of substantial heterogeneity. CARDIA, Coronary Artery Risk Development in Young Adults Study; HPFS, Health Professionals Follow-Up Study; NHS-I, Nurses' Health Study I; NHS-II, Nurses' Health Study II; SUN, Seguimiento Universidad de Navarra Project.
difference in the effects of liquid, solid, or mixed-form fructose on systolic, diastolic, or mean arterial blood pressures (11) in caloriematched comparisons with other carbohydrates that are likely to replace fructose. In fact, pooled analyses indicated a modest benefit of fructose for blood pressure. In addition, no effect was shown for calorie-matched fructose intakes on serum uric acid (12), the primary intermediate through which fructose is thought to induce hypertension. A systematic review and meta-analysis of prospective cohorts also failed to show an association between total fructose intake from all sources and incident hypertension (13) . Although the NHS-I and NHS-II cohorts included in the current meta-analysis adjusted for fructose intake, an earlier report by Winkelmayer et al. (34) studied hypertension risk with SSB intakes in these same cohorts without adjusting for fructose and reported similar RRs at comparable exposures [12% vs. 11% for the NHS-I and 17% vs. 18% for the NHS-II between $1 SSB/d in Cohen et al. (20) and weighted pooling of 1, 2-3, and $4 SSBs/d in Winkelmayer et al. (34) ], suggesting minimal impact of adjusting for fructose. Moreover, a significant trend of hypertension risk reduction was reported in the NHS-II when sources of fructose excluded SSBs, and a significant harmful trend in the NHS-I and NHS-II when sources of fructose intake included only SSBs (20) . Because fructose does not differ biochemically between the 2 sources, these findings implicate a mechanism independent of the amount of ingested fructose.
Subgroup analyses and dose responses
Although we observed significant between-cohort heterogeneity, wewere unable to explain it with our a priori subgroup analyses. Because of the limited number of cohorts and the methodologic homogeneity between them, only 2 subgroup analyses were possible; post hoc meta-regressions were impractical. We observed a significant linear dose-response between SSB intake and incident hypertension in the pooling of all but the CARDIA cohort. Our data suggest a 0.27% increase in risk per additional SSB per month or an 8.2% risk increase per additional SSB per day. With consideration of the large weight that the CARDIA cohort accounted for in our primary analysis, we acknowledged that its inclusion may have modified this observed dose-response relation. These data support previously suggested benefits of consuming fewer SSBs (35) . However, it is unclear whether similar benefits can be observed simply through an improved dietary pattern (30) , a reduction of caloric intake irrespective of source (36, 37) , or a reduction of overall sugar intake (38, 39) .
Limitations
Several limitations of our meta-analysis must be acknowledged. First, the examination of diseases with multifactorial causes in relation to single nutrients in prospective designs may have limited methodologic merit because of confounding from background dietary patterns (40) . Second, 94% of all individuals were of US nationality, 93% were health professionals, and 90% were Caucasian, limiting the generalizability of these results to a broader demographic (41) . Third, the relatively small number of available cohorts limited our ability to sufficiently explore relations between subgroups. Fourth, 2 of 5 cohorts did not adjust for sodium intake, and the remaining 3 cohorts adjusted for sodium intake with the use of only self-reported data from food-frequency questionnaires as opposed to the gold standard of 24-h urinary sodium (20) . Because sodium correlates with sugar and SSBs intake (39), the possibility of confounding by sodium intake could not be eliminated. Last, because all cohorts in the current meta-analysis pooled individuals who consumed $1-SSB/d, it is possible that our results underestimated risk in individuals with very high SSB intakes.
Implications
The risk increase reported in this meta-analysis must be considered in relation to other risk factors for hypertension. Multivariate-adjusted extreme quantile risk ratios for developing hypertension within cohorts included in this meta-analysis were 1.61 (95% CI: 1.42, 1.82) for alcohol consumption (42) (31, 46) .
In conclusion, this systematic review and meta-analysis of 6 prospective cohorts showed a significant 12% increase in risk of developing hypertension with $1-SSB/d in both men and women with no history of hypertension. We showed a significant doseresponse relation suggesting an 8.2% increase in risk per SSB per day across an SSB intake range from none to $1 SSB/d. This association is small in the context of other established risk factors for hypertension. There is a need for more-specific analyses within existing cohorts to further elucidate the relation between different sugar sources and incident hypertension within different demographics, particularly after adjusting for electrolyte intakes. High-quality, long-term, randomized controlled trials that assess the effects of reducing calories from SSBs vs. from other sources of solid calories on the development of hypertension and its complications are also warranted.
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